Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 M^pro Inhibitors.

ABSTRACT: The SARS-CoV-2 main protease (M^pro) has been proven to be a highly effective target for therapeutic intervention, yet only one drug currently holds FDA approval status for this target. We were inspired by a series of publications emanating from the Jorgensen and Anderson groups describing the design of potent, non-peptidic, competitive SARS-CoV-2 M^pro inhibitors, and we saw an opportunity to make several design modifications to improve the overall pharmacokinetic profile of these compounds without losing potency. To this end, we created a focused virtual library using reaction-based enumeration tools in the Schrödinger suite. These compounds were docked into the M^pro active site and subsequently prioritized for synthesis based upon relative binding affinity values calculated by FEP+. Fourteen compounds were selected, synthesized, and evaluated both biochemically and in cell culture. Several of the synthesized compounds proved to be potent, competitive M^pro inhibitors with improved metabolic stability profiles.

SUBMITTER: Jacobs L 

PROVIDER: S-EPMC10577883 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature